Conversational Autonomous Robots in GMP Manufacturing

The practical gap inside digital GMP environments

Anyone who has worked a cleanroom shift knows the moment: gloves on, gown sealed, and you need to check a procedure — but the nearest terminal is two airlocks away. Pharmaceutical manufacturing has gone digital in many ways, but the human interface inside GMP environments has not kept up. Operators in cleanrooms, warehouses, and QC labs regularly need SOPs, batch records, deviation procedures, and safety protocols while gowned, gloved, or simply nowhere near a workstation.

That’s a real problem. The information exists — and it’s usually governed by quality systems — but it is not always reachable at the exact point of work. A fixed terminal, a printed binder, or a call to the supervisor may get the job done, but each one adds friction. And in regulated operations, friction adds up: slower execution, heavier training burden, and documentation practices that are harder to sustain shift after shift.

Start with use cases, not the robot

Nobody needs a generic “robot assistant.” What they need is help with specific, repetitive, quality-sensitive tasks where the operator has to get the right approved answer without breaking the flow of work. Five use cases keep coming up in early GMP conversations:

These are credible starting points because they map to pain that every GMP team already knows, and they create a natural validation boundary. The system should not release product, approve deviations, or replace QA judgment. It should pull up the right controlled information, present it in context, log the interaction, and route exceptions to the right human.

What a shift could look like

In practice, you would probably start with cleanroom-adjacent and warehouse workflows before moving into higher-classified spaces. The scenarios below are illustrative, but they show why mobility, voice, and source-linked retrieval belong in the same conversation.

Why voice-first access matters

Voice-first AI fits here because it matches how people actually work on the floor. An operator should be able to say, “What’s the approved cleaning step before material transfer?” or “Which section covers this hold time?” and get an answer that points straight back to the controlled source document.

The key phrase there is “points straight back.” In GMP, an AI system is not a general-purpose adviser and it is definitely not a substitute for QA judgment. Its value lives or dies on whether it can retrieve the right approved source, show where it came from, respect document versions, and stay inside a validated envelope.

Why robotics changes the interface

Adding a robot to the mix gives the AI a body. It can move through the facility, show information on a screen, talk to the operator, and go where the work is — instead of waiting for the operator to come to it. More importantly, it can follow the material. In a typical flow, a drum moves from receiving dock to quarantine hold to sampling suite to released storage. A fixed terminal stays in one room. An autonomous robot can escort the material through each handoff, carrying the relevant document context with it and maintaining a visual chain of custody the entire way. The robot by itself is not the point. The question is whether that kind of continuity — mobility plus governed document retrieval across zones — can reduce friction that no fixed interface ever will.

For most facilities, the realistic starting point is cleanroom-adjacent rather than fully aseptic: warehouse quarantine, QC sampling, training rooms, gowning corridors, material staging, and audit walkdowns. Those environments are demanding enough to generate real feedback while giving quality teams time to figure out cleaning protocols, cybersecurity, access control, and record-management requirements before anyone rolls a robot into a classified suite.

The Oncotelic and TechForce development effort

This is what we are building toward. Oncotelic Therapeutics, through its subsidiary SAPU Bioscience, has signed a Joint Development Agreement with TechForce Robotics to explore this interface for regulated pharma environments. We bring the AI — SAPU’s PDAOAI Cortex platform — and TechForce brings the robots.

PDAOAI Cortex is a retrieval-based AI platform built to query controlled document sets — SOPs, batch records, regulatory references, technical files. In our prototype, the operator speaks a question, the system finds the relevant passages in an indexed document corpus, and a language model generates a spoken and on-screen response. Everything runs on facility-controlled infrastructure, so your regulated documents never leave the building.

TechForce brings the physical layer: autonomous navigation, operator-facing displays, and mobile interaction in real environments. Together, we are testing whether AI-enabled robots can become a practical interface for controlled information — not just a conference demo, but something that works on the floor.

Compliance must be designed in, not asserted afterward

Let’s be direct about this. For pharma manufacturers, the most important question is not whether the system can answer a question during a demo. It is whether the system can be configured, validated, and governed in a way that meets GMP expectations.

Where electronic records or electronic signatures are implicated, 21 CFR Part 11 considerations may include system validation, access controls, audit trails, record retention, authority checks, and change control. Local deployment can help reduce exposure of regulated documents and support data-security objectives, but local deployment alone does not establish compliance. Any production implementation would require site-specific qualification, quality oversight, cybersecurity review, and a clear definition of the system’s intended use.

This is especially important for AI. A credible GMP AI system must distinguish retrieved source content from generated language, avoid unsupported answers, preserve links back to controlled documents, and provide a human-review pathway for decisions that affect quality, safety, or product release.

What needs to be proven

We are not pretending this is ready to deploy tomorrow. Before AI-enabled robotics can move from concept to routine GMP use, the industry needs answers to some hard practical questions: How accurate are responses against controlled documents? How fast? Does voice recognition work in a noisy fill suite? Can you clean the robot to the required standard? Does it play nicely with your existing QMS?

The commercial case needs discipline too. The winning use cases will be the ones where the platform measurably reduces time spent hunting for information, improves training consistency, cuts documentation errors, or speeds up investigations — without compromising quality oversight. Demos are nice. Adoption depends on operational proof and a validation pathway that your quality team can defend to an auditor.

BIO 2026 as a feedback point

We will be showing the joint platform live at BIO 2026 in San Diego — California Life Sciences Pavilion, Booth #1525. You will be able to talk to the robot, see voice-based document retrieval in action, and judge for yourself whether this belongs in your facility. But the real reason we are there is to listen: which use cases matter most to you, what validation requirements keep you up at night, and where the gaps are that we have not thought of yet.

The goal is not to make GMP operations look futuristic. It is to make the right information available, traceable, and usable at the exact moment someone on the floor needs it.

Priority development questions for industry partners